Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. General Biologicals's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$1,189.3 Mil. General Biologicals's average total tangible assets for the quarter that ended in Dec. 2025 was NT$4,152.4 Mil. Therefore, General Biologicals's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 28.64%.
The historical rank and industry rank for General Biologicals's Return-on-Tangible-Asset or its related term are showing as below:
ROCO:4117'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -34.76 Med: -8.75 Max: 12.09
Current: 11.91
During the past 13 years, General Biologicals's highest Return-on-Tangible-Asset was 12.09%. The lowest was -34.76%. And the median was -8.75%.
ROCO:4117's Return-on-Tangible-Asset is ranked better than 83.52% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.95
vs ROCO:4117: 11.91
General Biologicals (ROCO:4117) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
General Biologicals Return-on-Tangible-Asset Related Terms
General Biologicals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for General Biologicals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
General Biologicals Return-on-Tangible-Asset Chart
ROCO:4117 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, General Biologicals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
General Biologicals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, General Biologicals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where General Biologicals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 28.64% mean?
General Biologicals (ROCO:4117) has a Return-on-Tangible-Asset of 28.64% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on General Biologicals and its competitors. According to the industry distribution chart, General Biologicals ranks #166 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 16.5%.
Is General Biologicals' Return-on-Tangible-Asset too high?
General Biologicals' current Return-on-Tangible-Asset is 28.64%. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.95. General Biologicals' value of 28.64% is 870.8% above this industry median. Based on the distribution chart, General Biologicals ranks #166 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, General Biologicals has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does General Biologicals' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, General Biologicals ranks #166 out of 1007 companies for Return-on-Tangible-Asset. This places General Biologicals in the top 17% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.95. General Biologicals' value of 28.64% is 870.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.95, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. General Biologicals's current Return-on-Tangible-Asset of 28.64% is 870.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on General Biologicals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. General Biologicals's current Return-on-Tangible-Asset is 28.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is General Biologicals stock overvalued right now?
Based on GuruFocus' analysis, General Biologicals (ROCO:4117) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$13.89, compared to a current price of NT$10.55 — trading 24% below its estimated fair value. The current Return-on-Tangible-Asset is 28.64% and 870.8% above the Drug Manufacturers industry median of 2.95. General Biologicals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For General Biologicals (ROCO:4117), the current Return-on-Tangible-Asset is 28.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is General Biologicals (ROCO:4117) Overvalued in 2026?
Based on GuruFocus' analysis, General Biologicals stock appears to be undervalued.
The current stock price of NT$10.55 is trading 24% below its estimated GF Value™ of NT$13.89.
GuruFocus considers General Biologicals to be Modestly Undervalued.
Key valuation signals for ROCO:4117:
Return-on-Tangible-Asset: 28.64%
GF Value™: NT$13.89 vs. price of NT$10.55 (24% below fair value)
Industry Position: 870.8% above the Drug Manufacturers median (#166 of 1007)
No single metric tells the full story. See the ROCO:4117 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
General Biologicals Corp is a developer and manufacturer of vitro diagnostic devices in Taiwan. It offers research development, marketing and servicing of products and solutions for hospitals, medical laboratories, blood banks, and research and industry. Its products include Anti-HDV, HIV Ag-Ab COMB, Anti-HBs, and many others.
46GF Score
Get the complete analysis for ROCO:4117
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4117 has been successfully added to your 
